|
Biocardia Inc (NASDAQ: BCDA) |
|
Biocardia Inc
BCDA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Biocardia Inc 's sales fell
in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2703
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -2.45 %
Biocardia Inc net loss increased from $-2 millions, to $-2 millions in IV. Quarter 2024,
• More on BCDA's Growth
|
|
Biocardia Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 4.43 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 96.84.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.02.
• More on BCDA's Valuation
|
|
|
|
|
Biocardia Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 4.43 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 96.84.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.02.
Biocardia Inc Price to Book Ratio is at 6.71 lower than Industry Avg. of 17782.13. and higher than S&P 500 Avg. of 0.01
• More on BCDA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com